Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-term beinaglutide infusion in acute ischemic stroke with hyperglycemia
ChiCTR2300074691Phase 4Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of beinaglutide in ischemic stroke (2 arms), sponsored by Peking University First Hospital. Primary endpoints: Proportion of patients with modified Rankin Scale score <=3 at day 90 and Proportion achieving mean 24-hour glucose target range >70% during treatment without hypoglycemia. Started Jun 2023; status: recruiting.
02
Drugs
beinaglutide
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2300074691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074691.